These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 35876293

  • 1. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D, Bengtson LGS, Conoscenti CS, Anderson AJ, Brekke L, Shetty SS, Brown KK.
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [Abstract] [Full Text] [Related]

  • 2. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M, Steffens A, Anderson A, Brekke L, Grace Johnson M, Veeranki P, Olson AL.
    J Manag Care Spec Pharm; 2024 Feb 03; 30(2):163-174. PubMed ID: 38308627
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Economic Burden of Illness in Adult Patients with Nocturia.
    Dmochowski R, Brucker BM, Cole E, Kawahara S, Pulicharam R, Burk C, Tung A, Hale D.
    J Manag Care Spec Pharm; 2019 May 03; 25(5):593-604. PubMed ID: 30675816
    [Abstract] [Full Text] [Related]

  • 12. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V.
    Curr Med Res Opin; 2019 Nov 03; 35(11):2015-2024. PubMed ID: 31328965
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
    To TM, Exuzides A, Abbass IM, Patel AM, Ta JT, Surinach A, Fuller RLM, Luo J.
    J Manag Care Spec Pharm; 2022 Nov 03; 28(11):1228-1239. PubMed ID: 36282937
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C.
    Dan Med J; 2015 Apr 03; 62(4):B5069. PubMed ID: 25872544
    [Abstract] [Full Text] [Related]

  • 18. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S, Ghosh S, Sander S, Kuti E, Mountford WK.
    J Manag Care Spec Pharm; 2018 Mar 03; 24(3):280-290. PubMed ID: 29485954
    [Abstract] [Full Text] [Related]

  • 19. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
    Lancet Respir Med; 2020 May 03; 8(5):453-460. PubMed ID: 32145830
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.